Rocket Pharmaceuticals(US:RCKT) Prnewswireยท2025-07-10 13:00Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price after the FDA placed a clinical hold on the study following a Serious Adverse Event [2][3]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) [2]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to inflated stock prices [2]. - Following the announcement of a clinical hold by the FDA due to a patient's death linked to the trial, Rocket's stock price plummeted from $6.27 on May 23, 2025, to $2.33 on May 27, 2025, marking a decline of approximately 37% in one trading day [2]. Class Action Details - The class period for the lawsuit is defined as February 27, 2025, to May 26, 2025, with a deadline for shareholders to register for the class action by August 11, 2025 [3]. - Shareholders who register will receive updates on the case's progress through portfolio monitoring software [3]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions that led to artificial inflation of stock prices [4].